EQL — EQL Pharma AB Cashflow Statement
0.000.00%
- SEK2.48bn
- SEK2.85bn
- SEK373.52m
Annual cashflow statement for EQL Pharma AB, fiscal year end - March 31st, SEK millions except per share, conversion factor applied.
C2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | PRESS |
Standards: | SAS | IFRS | IFRS | IFRS | — |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | 10.4 | 36 | 39 | 32.6 | 67.4 |
Depreciation | |||||
Non-Cash Items | 18.4 | 13 | 14.2 | -5.83 | 12.5 |
Other Non-Cash Items | |||||
Changes in Working Capital | 31.3 | -7.18 | -25.5 | -47 | -105 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | 60 | 41.8 | 27.6 | -11.4 | -24.7 |
Capital Expenditures | -55.6 | -22.1 | -20.5 | -66.3 | -246 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | — | — | -0.001 | — | -0.001 |
Other Investing Cash Flow | |||||
Cash from Investing Activities | -55.6 | -22.1 | -20.5 | -66.3 | -246 |
Financing Cash Flow Items | — | — | 0.001 | — | 0.001 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 11.8 | -5.12 | -3.88 | 53.7 | 332 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 16.3 | 14.6 | 3.23 | -24 | 61.9 |